Gleevec
-
[Joint Statement] Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity - Welcome the ruling of the Supreme Court of India
2013/04/02The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and against Indian Patent law has finally reached a conclusion. On Apr1, Indian Supreme court dismissed Novartis’ appeal.
-
Stop the India-EU FTA Negotiations, Decimator of the 'Pharmacy of the World'!
2011/11/27US and EU are threatening lives of people living with disease now. The India-EU FTA is an agreement which risk patients' health none the more than the KORUS FTA. Especially, the India-EU FTA endangers lives of people living with disease all over the world. We urge the Lee Myoung-bak government to abolish KORUS FTA immediately as well as the India government to stop the India-EU FTA negotiation. We also call for the India Supreme Court to dismiss Swiss pharmaceutical company, Novartis' case toward India's progressive patent law.
-
[Letter] Joint Letter of Korean NGOs to the Indian Embassy in Seoul
2007/01/29On behalf of the 27 Korean NGOs, Trade Unions, I am writing to express our concerns regarding the legal proceedings that Norvatis initiated in India in May 2006, challenging the rejection of its patent application for imatinib mesylate (Gleevec/Glivec) as well as questioning the compliance of the Indian Patents Act with the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights(TRIPS).
-
Struggle for Access to Glivec
2003/09/25Struggle for Access to Glivec in South Korea Solidarity Needed Now!!!
-
Patents and Profit: Gleevec Price Talks Break Down.
2002/11/08The National Health Insurance System Board held talks on September 6 to try decide the retail price of Gleevec, a cancer drug used for treating leukemia, only to end by delaying the talks even further. One year has passed since the problem of Gleevec first arose.
-
Novartis's stubborn Gleevec price means death to patients
2002/08/01Only by this kind of public support was Novartis able to recollect all invested capital within eight months of global marketing of Gleevec. But now, Novartis has twenty years of intellectual property rights.